Pub Date : 2023-08-15DOI: 10.18231/j.ijogr.2023.060
Neha Gupta, U. Pandey, Shivi Jain, S. Singh
: Transvaginal ultrasound is an important part of the Rotterdam criteria, which are commonly used to diagnose polycystic ovary syndrome (PCOS). Specifically, the presence of polycystic ovarian morphology (PCOM) is a key factor in the criteria. Another useful indicator of PCOM is the Anti-Mullerian hormone (AMH) level.The objective is to evaluate the diagnostic accuracy of serum Anti-Mullerian hormone (AMH) in identifying polycystic ovary syndrome (PCOS) and determine whether it can be used as a substitute for polycystic ovarian morphology (PCOM) in the Rotterdam criteria. Additionally, we aim to investigate the relationship between AMH levels and hyperandrogenism in PCOS patients.A study was out in SSH BHU various parameters will be used in diagnosis. Serum AMH Radiology: By Transvaginal Sonography single observer obtained dimensions for ovarian volume and the maximum number of follicles in one section. AMH levels will be estimated using commercially available Gen-II ELISA assay. Biochemical evaluation will be done in the Department of Bio-Chemistry IMS BHU. The Anti-Mullerian hormone (AMH) serum levels will be measured using a commercially available ultra-sensitive Gen-II enzyme-linked immunosorbent assay (ELISA) kit from Beckman Coulter, CA. The ELISA has a lower limit of detectability (LoD) of 0.08 ng/ml, a lower limit of quantification (LoQ) of 0.17 mg/ml, and an intra-assay coefficient of variation of 5.8%. The unit of measurement is ng/mL (1ng/mL=7.14 pmol/L). The study showed that Anti-Mullerian hormone (AMH) levels were markedly higher in individuals with polycystic ovary syndrome (PCOS) than in controls. While AMH alone was not a reliable diagnostic marker for PCOS, the findings suggested that incorporating AMH levels as an additional factor in the existing Rotterdam criteria could improve the accuracy of PCOS diagnosis. Therefore, AMH levels have the potential as a useful adjunct marker for the diagnosis of PCOS.
{"title":"Role of anti mullerian hormone (AMH) in diagnosis of polycystic ovarian syndrome (PCOS) in Indian women","authors":"Neha Gupta, U. Pandey, Shivi Jain, S. Singh","doi":"10.18231/j.ijogr.2023.060","DOIUrl":"https://doi.org/10.18231/j.ijogr.2023.060","url":null,"abstract":": Transvaginal ultrasound is an important part of the Rotterdam criteria, which are commonly used to diagnose polycystic ovary syndrome (PCOS). Specifically, the presence of polycystic ovarian morphology (PCOM) is a key factor in the criteria. Another useful indicator of PCOM is the Anti-Mullerian hormone (AMH) level.The objective is to evaluate the diagnostic accuracy of serum Anti-Mullerian hormone (AMH) in identifying polycystic ovary syndrome (PCOS) and determine whether it can be used as a substitute for polycystic ovarian morphology (PCOM) in the Rotterdam criteria. Additionally, we aim to investigate the relationship between AMH levels and hyperandrogenism in PCOS patients.A study was out in SSH BHU various parameters will be used in diagnosis. Serum AMH Radiology: By Transvaginal Sonography single observer obtained dimensions for ovarian volume and the maximum number of follicles in one section. AMH levels will be estimated using commercially available Gen-II ELISA assay. Biochemical evaluation will be done in the Department of Bio-Chemistry IMS BHU. The Anti-Mullerian hormone (AMH) serum levels will be measured using a commercially available ultra-sensitive Gen-II enzyme-linked immunosorbent assay (ELISA) kit from Beckman Coulter, CA. The ELISA has a lower limit of detectability (LoD) of 0.08 ng/ml, a lower limit of quantification (LoQ) of 0.17 mg/ml, and an intra-assay coefficient of variation of 5.8%. The unit of measurement is ng/mL (1ng/mL=7.14 pmol/L). The study showed that Anti-Mullerian hormone (AMH) levels were markedly higher in individuals with polycystic ovary syndrome (PCOS) than in controls. While AMH alone was not a reliable diagnostic marker for PCOS, the findings suggested that incorporating AMH levels as an additional factor in the existing Rotterdam criteria could improve the accuracy of PCOS diagnosis. Therefore, AMH levels have the potential as a useful adjunct marker for the diagnosis of PCOS.","PeriodicalId":13288,"journal":{"name":"Indian Journal of Obstetrics and Gynecology Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89576334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-15DOI: 10.18231/j.ijogr.2023.072
Reshmi Mohanan, P. Hiremath, N. Indu, M. Sreesupriya, R. Hiremath
The incidence of ovarian tumor in pregnancy is 2.4-5.7%of which 5% are malignant. A 26-year-old primigravida was diagnosed with benign ovarian cyst during first trimester ultrasound. Elective LSCS with left oophorectomy was performed. Histopathological examination revealed malignant ovarian tumor (high grade serous carcinoma). The objective of this report is to highlight the importance of early diagnosis and management of ovarian tumor in pregnancy.
{"title":"A case report on a rare case of malignant ovarian tumour complicating pregnancy","authors":"Reshmi Mohanan, P. Hiremath, N. Indu, M. Sreesupriya, R. Hiremath","doi":"10.18231/j.ijogr.2023.072","DOIUrl":"https://doi.org/10.18231/j.ijogr.2023.072","url":null,"abstract":"The incidence of ovarian tumor in pregnancy is 2.4-5.7%of which 5% are malignant. A 26-year-old primigravida was diagnosed with benign ovarian cyst during first trimester ultrasound. Elective LSCS with left oophorectomy was performed. Histopathological examination revealed malignant ovarian tumor (high grade serous carcinoma). The objective of this report is to highlight the importance of early diagnosis and management of ovarian tumor in pregnancy.","PeriodicalId":13288,"journal":{"name":"Indian Journal of Obstetrics and Gynecology Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76350610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-15DOI: 10.18231/j.ijogr.2023.068
M. Pandya, Vidya Pancholiya, Nehal Manish Pandya, Roma S. Dadwani, Khushbu K Patel, Z. Vizintin, Hari Krishna
: Genitourinary Syndrome of Menopause (GSM) is the condition which combines the conditions of vulvovaginal atrophy (VVA) and urinary tract dysfunction which are associated with oestrogen deficiency. GSM is treated using vaginal laser therapy by using non-ablative Er: YAG laser therapy to evaluate the effectiveness and safety of this therapy. The present study was planned to evaluate the safety and objective improvement in symptoms of GSM with Er:yag vaginal / urethral laser treatment in sextual and urinary symptoms of post / peri menopausal women on long term basis. A prospective study was conducted at V care laser centre from 2020 on words to till date. Total sample population enrolled was 74 among them 53 completed 1 follow up and 29 had completed 2 follow up. Data were collected before and subsequent 2 follow ups over next 12 months on parameters like dryness, dyspareunia, itching/ burning and lower urinary tract symptoms, data were collected using VLQ (vaginal laxity questionnaire), VHIS (vaginal health index score), FSDS-R (The female sexual distress scale – revised)and Satisfaction questionnaire (0-3) assessed on FSFI. : The study showed symptomatic improvement among patients with GSM like no pain or mild pain among 79.31% and 20.39% respectively, no itching (72.41%) at the end of 2 follow up. There was an improvement in vaginal condition (normal – 93.10%) at the end of 2 follow up. Majority of patients reported no sexual distress (82.7%). : The non-ablative Er: YAG laser therapy is efficacious and safe modality for treatment of symptoms in cases of genitourinary syndrome of menopause. It also offers a promising, minimally invasive safe treatment for SUI.
{"title":"Prospective study of safety and objective improvement in sysmptoms of GSM (Genitourinary syndrome of menopause) withEr:YAG vaginal /urethral laser treatment","authors":"M. Pandya, Vidya Pancholiya, Nehal Manish Pandya, Roma S. Dadwani, Khushbu K Patel, Z. Vizintin, Hari Krishna","doi":"10.18231/j.ijogr.2023.068","DOIUrl":"https://doi.org/10.18231/j.ijogr.2023.068","url":null,"abstract":": Genitourinary Syndrome of Menopause (GSM) is the condition which combines the conditions of vulvovaginal atrophy (VVA) and urinary tract dysfunction which are associated with oestrogen deficiency. GSM is treated using vaginal laser therapy by using non-ablative Er: YAG laser therapy to evaluate the effectiveness and safety of this therapy. The present study was planned to evaluate the safety and objective improvement in symptoms of GSM with Er:yag vaginal / urethral laser treatment in sextual and urinary symptoms of post / peri menopausal women on long term basis. A prospective study was conducted at V care laser centre from 2020 on words to till date. Total sample population enrolled was 74 among them 53 completed 1 follow up and 29 had completed 2 follow up. Data were collected before and subsequent 2 follow ups over next 12 months on parameters like dryness, dyspareunia, itching/ burning and lower urinary tract symptoms, data were collected using VLQ (vaginal laxity questionnaire), VHIS (vaginal health index score), FSDS-R (The female sexual distress scale – revised)and Satisfaction questionnaire (0-3) assessed on FSFI. : The study showed symptomatic improvement among patients with GSM like no pain or mild pain among 79.31% and 20.39% respectively, no itching (72.41%) at the end of 2 follow up. There was an improvement in vaginal condition (normal – 93.10%) at the end of 2 follow up. Majority of patients reported no sexual distress (82.7%). : The non-ablative Er: YAG laser therapy is efficacious and safe modality for treatment of symptoms in cases of genitourinary syndrome of menopause. It also offers a promising, minimally invasive safe treatment for SUI.","PeriodicalId":13288,"journal":{"name":"Indian Journal of Obstetrics and Gynecology Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78859661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-15DOI: 10.18231/j.ijogr.2023.056
Ushadevi Gopalan, Sangeetha Marimuthu
Leiomyoma or uterine fibroid are benign tumours that arise from the smooth muscles of the uterus. The leiomyomas are common gynaecological problem encountered among reproductive age group women. Mifepristone is the commonly used drug in the management of uterine leiomyoma. The objective of the study were to study the efficacy and safety of 10mg and 25mg of Mifepristone in the management of uterine fibroid. This is a randomized controlled Trial conducted in tertiary care centre. Hundred women with the diagnosis of uterine fibroid were taken up for the study. Group-A (n=50) were given Mifepristone 10mg and Group-B (n=50) were given Mifepristone 25mg daily for a period of 3 months. Reduction in the size of fibroid were assessed at the end of 3 months. At the end of 3months there was a significant reduction in both menstrual blood loss and fibroid volume in both the groups (p<0.001). There was a also significant improvement in haemoglobin levels in both the groups. When compared to Group –A (10mg Mifepristone) more side effects were noted in Group-B (25mg Mifepristone). Nausea and vomiting developed in 90% and 60% of patients in group A and B.Gastrointestinal discomfort developed in 80% and 50% of patients in group A and B. Both Mifepristone 10mg and 25mg had similar clinical outcomes but 10mg had better compliance and lower side effects. Hence, 10mg can be preferred over 25mg in order to bring about effective management of uterine fibroid.
{"title":"Efficacy of different doses of mifepristone in the management of uterine leiomyoma in a tertiary care centre","authors":"Ushadevi Gopalan, Sangeetha Marimuthu","doi":"10.18231/j.ijogr.2023.056","DOIUrl":"https://doi.org/10.18231/j.ijogr.2023.056","url":null,"abstract":"Leiomyoma or uterine fibroid are benign tumours that arise from the smooth muscles of the uterus. The leiomyomas are common gynaecological problem encountered among reproductive age group women. Mifepristone is the commonly used drug in the management of uterine leiomyoma. The objective of the study were to study the efficacy and safety of 10mg and 25mg of Mifepristone in the management of uterine fibroid. This is a randomized controlled Trial conducted in tertiary care centre. Hundred women with the diagnosis of uterine fibroid were taken up for the study. Group-A (n=50) were given Mifepristone 10mg and Group-B (n=50) were given Mifepristone 25mg daily for a period of 3 months. Reduction in the size of fibroid were assessed at the end of 3 months. At the end of 3months there was a significant reduction in both menstrual blood loss and fibroid volume in both the groups (p<0.001). There was a also significant improvement in haemoglobin levels in both the groups. When compared to Group –A (10mg Mifepristone) more side effects were noted in Group-B (25mg Mifepristone). Nausea and vomiting developed in 90% and 60% of patients in group A and B.Gastrointestinal discomfort developed in 80% and 50% of patients in group A and B. Both Mifepristone 10mg and 25mg had similar clinical outcomes but 10mg had better compliance and lower side effects. Hence, 10mg can be preferred over 25mg in order to bring about effective management of uterine fibroid.","PeriodicalId":13288,"journal":{"name":"Indian Journal of Obstetrics and Gynecology Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72547847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-15DOI: 10.18231/j.ijogr.2023.073
Angela Devanboo, Dhriti Chendil Nathan, Shweta Mahalingam, Vishal Prabhu, Hema Purandarey, E. Venkataswamy, V. Ramprasad, P. Kadam
Non-invasive prenatal test (NIPT) has become a popular screening test worldwide for screening common trisomies. In addition, the test can also sex chromosomal aneuploidies (SCAs) with similar sensitivity. In recent years, the scope of NIPT has extended to screen pregnancies for clinically significant microdeletions (MDs), rare autosomal aneuploidies, and subchromosomal abnormalities. The clinical utility of NIPT screening beyond trisomies 21,18,13 and SCAs are still being evaluated because of low positive predictive value which in turn leads to an increase in invasive procedures. Here, we present a case where SNP - NIPT correctly identified a microdeletion syndrome, i.e., 22q11.2DS in a pregnant woman with normal ultrasound findings. This NIPT finding was further confirmed in the chromosomal microarray study and FISH.
{"title":"Detection of 22q11.2 deletion syndrome by single-nucleotide polymorphism based non-invasive prenatal test","authors":"Angela Devanboo, Dhriti Chendil Nathan, Shweta Mahalingam, Vishal Prabhu, Hema Purandarey, E. Venkataswamy, V. Ramprasad, P. Kadam","doi":"10.18231/j.ijogr.2023.073","DOIUrl":"https://doi.org/10.18231/j.ijogr.2023.073","url":null,"abstract":"Non-invasive prenatal test (NIPT) has become a popular screening test worldwide for screening common trisomies. In addition, the test can also sex chromosomal aneuploidies (SCAs) with similar sensitivity. In recent years, the scope of NIPT has extended to screen pregnancies for clinically significant microdeletions (MDs), rare autosomal aneuploidies, and subchromosomal abnormalities. The clinical utility of NIPT screening beyond trisomies 21,18,13 and SCAs are still being evaluated because of low positive predictive value which in turn leads to an increase in invasive procedures. Here, we present a case where SNP - NIPT correctly identified a microdeletion syndrome, i.e., 22q11.2DS in a pregnant woman with normal ultrasound findings. This NIPT finding was further confirmed in the chromosomal microarray study and FISH.","PeriodicalId":13288,"journal":{"name":"Indian Journal of Obstetrics and Gynecology Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73013175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-15DOI: 10.18231/j.ijogr.2023.053
U. Pandey, Aditi Narayan, S. Lindow
: Domestic violence is a social evil prevalent across all cultures and societies. It refers to any form of physical or mental abuse suffered by a person from a relative or member of their domestic circle. The majority of the world is patriarchal and women are most affected. The present study was done to evaluate the attitudes and experiences of domestic violence amongst staff of SSH and IMS. A total of 392 staff were questioned regarding their attitudes and experiences of Domestic Violence victims. The study was a cross observational study and questionnaires were distributed via Google Forms and were filled anonymously. The responses collected were categorized on the basis of the student and qualified staff members of SSH and IMS. The data obtained was subjected to statistical analysis using SPSS software.: Qualified healthcare professionals (53%) had more exposure to domestic violence victims than students (28%) and were aware (51%) that inquiring about DV was essential in their job. However, they were more concerned (33%) about potential impacts on patient relationships than students (32%). Both groups preferred seeking help from friends/family (48%) over the police (28%) for DV victims. Students were more proactive in reporting DV to the police. More qualified professionals (44%) believed government efforts to address DV were inadequate, while students (60%) saw room for improvement. COVID-19 worsened DV according to 61% of students and 42% of professionals. Both groups acknowledged DV inquiry as part of their job and supported hospital-based help, with students (35%) favoring dedicated services for IPV victims more than professionals (29%). Both groups lacked sufficient DV training in their curriculum (42%).: Domestic violence persists as a social menace, often seen as a private matter despite available government and non-government efforts. The COVID-19 pandemic has exacerbated the situation for victims. Hospital support and healthcare professionals' training are lacking. Our study assesses the impact of DV training, urging authorities to address this critical issue.
{"title":"Study of institute of medical sciences, BHU and Sir Sunder Lal Hospital staff regarding their attitudes and experiences of domestic violence","authors":"U. Pandey, Aditi Narayan, S. Lindow","doi":"10.18231/j.ijogr.2023.053","DOIUrl":"https://doi.org/10.18231/j.ijogr.2023.053","url":null,"abstract":": Domestic violence is a social evil prevalent across all cultures and societies. It refers to any form of physical or mental abuse suffered by a person from a relative or member of their domestic circle. The majority of the world is patriarchal and women are most affected. The present study was done to evaluate the attitudes and experiences of domestic violence amongst staff of SSH and IMS. A total of 392 staff were questioned regarding their attitudes and experiences of Domestic Violence victims. The study was a cross observational study and questionnaires were distributed via Google Forms and were filled anonymously. The responses collected were categorized on the basis of the student and qualified staff members of SSH and IMS. The data obtained was subjected to statistical analysis using SPSS software.: Qualified healthcare professionals (53%) had more exposure to domestic violence victims than students (28%) and were aware (51%) that inquiring about DV was essential in their job. However, they were more concerned (33%) about potential impacts on patient relationships than students (32%). Both groups preferred seeking help from friends/family (48%) over the police (28%) for DV victims. Students were more proactive in reporting DV to the police. More qualified professionals (44%) believed government efforts to address DV were inadequate, while students (60%) saw room for improvement. COVID-19 worsened DV according to 61% of students and 42% of professionals. Both groups acknowledged DV inquiry as part of their job and supported hospital-based help, with students (35%) favoring dedicated services for IPV victims more than professionals (29%). Both groups lacked sufficient DV training in their curriculum (42%).: Domestic violence persists as a social menace, often seen as a private matter despite available government and non-government efforts. The COVID-19 pandemic has exacerbated the situation for victims. Hospital support and healthcare professionals' training are lacking. Our study assesses the impact of DV training, urging authorities to address this critical issue.","PeriodicalId":13288,"journal":{"name":"Indian Journal of Obstetrics and Gynecology Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83285502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-15DOI: 10.18231/j.ijogr.2023.058
Mehak Reyaz, N. Nandi
Postmenopausal bleeding occurs in approximately 10% of postmenopausal women. Postmenopausal bleeding requires complete assessment to ensure the absence of malignancy. The aim of the study is to know the causes of postmenopausal bleeding based on Histopathological findings and the percentages of various benign, pre malignant and malignant lesions.This study included 53 cases attending the obstetrics & gynaecology department of TMU&RC, Moradabad western Uttar Pradesh with complaint of post menopausal bleeding over a time period of 2 years from July 2017-june 2019.Among benign cases, the most common cause was atrophic endometrium (39.6%). Among malignant cases, the most common cause was cervical malignancy (28.3%). Out of 53 cases, 26 cases account for premalignant and malignant causes of PMB, carcinoma cervix accounts for 53.7% and carcinoma in situ accounts for 3.8%.The postmenopausal bleeding is an important symptom and require careful and timely assessment to eliminate the possibility of malignancy as soon as possible.
{"title":"Histopathological spectrum of lesions in evaluating the women with postmenopausal bleeding","authors":"Mehak Reyaz, N. Nandi","doi":"10.18231/j.ijogr.2023.058","DOIUrl":"https://doi.org/10.18231/j.ijogr.2023.058","url":null,"abstract":"Postmenopausal bleeding occurs in approximately 10% of postmenopausal women. Postmenopausal bleeding requires complete assessment to ensure the absence of malignancy. The aim of the study is to know the causes of postmenopausal bleeding based on Histopathological findings and the percentages of various benign, pre malignant and malignant lesions.This study included 53 cases attending the obstetrics & gynaecology department of TMU&RC, Moradabad western Uttar Pradesh with complaint of post menopausal bleeding over a time period of 2 years from July 2017-june 2019.Among benign cases, the most common cause was atrophic endometrium (39.6%). Among malignant cases, the most common cause was cervical malignancy (28.3%). Out of 53 cases, 26 cases account for premalignant and malignant causes of PMB, carcinoma cervix accounts for 53.7% and carcinoma in situ accounts for 3.8%.The postmenopausal bleeding is an important symptom and require careful and timely assessment to eliminate the possibility of malignancy as soon as possible.","PeriodicalId":13288,"journal":{"name":"Indian Journal of Obstetrics and Gynecology Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85909847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-15DOI: 10.18231/j.ijogr.2023.051
Juhi Vipul Amin, A. Gokhale, Vidhi Hemantkumar Shah, Aayushi Jitendra Rajani
The purpose of this study is to compare the efficacy of oral Mifepristone with the efficacy of intracervical Foley catheterisation for induction of labour in term pregnancy. The primary outcome of this study is to compare both methods of induction of labour in terms of induction to delivery interval and the secondary outcome is to compare the two methods in terms of route of delivery, indications of caesarean section and the neonatal outcomes. This study is a randomized control trial conducted from May 2022 to December 2022 in Department of Obstetrics and Gynecology, SSG Hospital, Baroda Medical College. 180 term pregnant patients were enrolled in this study based on a pre-established criteria. Patients were randomised into group A and B. Group A included patients who were given Tablet Mifepristone 200 mg PO followed by per vaginum Tablet Misoprostol and Group B included patients who underwent intracervical Foleys catheterisation followed by placement of per vaginum Tablet Misoprostol. The study concluded that there was significantly decreased induction-delivery interval in women induced with intracervical Foleys catheterisation (Group B) as compared to those given oral Tablet Mifepristone (Group A). There was no significant difference between the two groups in terms of the route of delivery, rate of C Sections and neonatal outcomes.Mifepristone is effective for inducing indicated term pregnancies, despite no decrease in induction delivery interval. Incidence of fetal distress with oral Mifepristone is comparable to intracervical foley's catheterization. Further research is needed to assess tachysystole/hyperstimulation and fetal distress caused by Mifepristone.
{"title":"Comparison of oral mifepristone with intracervical foleys catheterisation for induction of labour in term pregnancy: A randomized control trial","authors":"Juhi Vipul Amin, A. Gokhale, Vidhi Hemantkumar Shah, Aayushi Jitendra Rajani","doi":"10.18231/j.ijogr.2023.051","DOIUrl":"https://doi.org/10.18231/j.ijogr.2023.051","url":null,"abstract":"The purpose of this study is to compare the efficacy of oral Mifepristone with the efficacy of intracervical Foley catheterisation for induction of labour in term pregnancy. The primary outcome of this study is to compare both methods of induction of labour in terms of induction to delivery interval and the secondary outcome is to compare the two methods in terms of route of delivery, indications of caesarean section and the neonatal outcomes. This study is a randomized control trial conducted from May 2022 to December 2022 in Department of Obstetrics and Gynecology, SSG Hospital, Baroda Medical College. 180 term pregnant patients were enrolled in this study based on a pre-established criteria. Patients were randomised into group A and B. Group A included patients who were given Tablet Mifepristone 200 mg PO followed by per vaginum Tablet Misoprostol and Group B included patients who underwent intracervical Foleys catheterisation followed by placement of per vaginum Tablet Misoprostol. The study concluded that there was significantly decreased induction-delivery interval in women induced with intracervical Foleys catheterisation (Group B) as compared to those given oral Tablet Mifepristone (Group A). There was no significant difference between the two groups in terms of the route of delivery, rate of C Sections and neonatal outcomes.Mifepristone is effective for inducing indicated term pregnancies, despite no decrease in induction delivery interval. Incidence of fetal distress with oral Mifepristone is comparable to intracervical foley's catheterization. Further research is needed to assess tachysystole/hyperstimulation and fetal distress caused by Mifepristone.","PeriodicalId":13288,"journal":{"name":"Indian Journal of Obstetrics and Gynecology Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73138289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-15DOI: 10.18231/j.ijogr.2023.064
P. Ramachandran, Anshu Sharma, P. Ravinder, M. Nair, K. Kalaivani
In India, prevalence of nutritional anaemia due to iron, folic acid and vitamin B12 deficiency is high. National anaemia control programme envisaged detection and treatment of anaemic pregnant women. Prevalence of anaemia continues to be high because this strategy was not operationalised and coverage and compliance with iron folic acid supplementation remains low. : The present study aimed at: 1. Operationalizing Hb estimation in urban maternity center, 2. assessing prevalence of iron, folic acid and vitamin B12 deficiency, 3. undertaking an open randomized study in women with Hb between 8.0 and 10.9 g/dL to assess impact of supplementation with iron and folic acid (Group 1) or iron, folic acid and vitamin B 12 (Group 2). The ‘Test and treat’ strategy was operationalized in urban maternity center. At enrolment 100% of women were anaemic, 60% had ferritin <12ng/ml, 5% had folic acid <3ng/ml and 1/3 had vitamin B12 <200pg/ml. After eight weeks of supplementation, there was an increase in mean Hb (>1.0 g/dL), mean ferritin and folic acid in both Gr 1 and 2. There was a fall in mean vitamin B12 at 8 weeks in Gr 1 women who received 5 mg folic acid. Addition of vitamin B12 to IFA does not improve mean Hb or vitamin B12.With assured regular supply and supportive supervision, iron folic acid supplementation for 8 weeks reduces prevalence of anaemia in pregnancy by 50%; with continued supplementation till 38 weeks of pregnancy, there was 70% reduction in prevalence of anaemia.
{"title":"Management of anaemia in pregnancy using ‘test and treat’ strategy: hospital based open randomized study","authors":"P. Ramachandran, Anshu Sharma, P. Ravinder, M. Nair, K. Kalaivani","doi":"10.18231/j.ijogr.2023.064","DOIUrl":"https://doi.org/10.18231/j.ijogr.2023.064","url":null,"abstract":"In India, prevalence of nutritional anaemia due to iron, folic acid and vitamin B12 deficiency is high. National anaemia control programme envisaged detection and treatment of anaemic pregnant women. Prevalence of anaemia continues to be high because this strategy was not operationalised and coverage and compliance with iron folic acid supplementation remains low. : The present study aimed at: 1. Operationalizing Hb estimation in urban maternity center, 2. assessing prevalence of iron, folic acid and vitamin B12 deficiency, 3. undertaking an open randomized study in women with Hb between 8.0 and 10.9 g/dL to assess impact of supplementation with iron and folic acid (Group 1) or iron, folic acid and vitamin B 12 (Group 2). The ‘Test and treat’ strategy was operationalized in urban maternity center. At enrolment 100% of women were anaemic, 60% had ferritin <12ng/ml, 5% had folic acid <3ng/ml and 1/3 had vitamin B12 <200pg/ml. After eight weeks of supplementation, there was an increase in mean Hb (>1.0 g/dL), mean ferritin and folic acid in both Gr 1 and 2. There was a fall in mean vitamin B12 at 8 weeks in Gr 1 women who received 5 mg folic acid. Addition of vitamin B12 to IFA does not improve mean Hb or vitamin B12.With assured regular supply and supportive supervision, iron folic acid supplementation for 8 weeks reduces prevalence of anaemia in pregnancy by 50%; with continued supplementation till 38 weeks of pregnancy, there was 70% reduction in prevalence of anaemia.","PeriodicalId":13288,"journal":{"name":"Indian Journal of Obstetrics and Gynecology Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78346492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-15DOI: 10.18231/j.ijogr.2023.050
Anna Zarfishan
Obesity is known as a prominent public health issue. It can be featured as an epidemic as it does no discrimination on the basis of age, gender, and socioeconomic status. Among pregnant females, incidence of obesity is getting increased and it is found to be linked with many complications that obstetricians are facing now-a-days. It also poses a huge confront to pregnant females as it is linked with unfavourable perinatal and maternal outcomes. Still, various studies revealed conflicting results between improvement in pregnancy outcome and lifestyle intervention. The objective of present review is to emphasize about complications, clinical significance and management of maternal obesity.
{"title":"Obesity in pregnant females- A review article","authors":"Anna Zarfishan","doi":"10.18231/j.ijogr.2023.050","DOIUrl":"https://doi.org/10.18231/j.ijogr.2023.050","url":null,"abstract":"Obesity is known as a prominent public health issue. It can be featured as an epidemic as it does no discrimination on the basis of age, gender, and socioeconomic status. Among pregnant females, incidence of obesity is getting increased and it is found to be linked with many complications that obstetricians are facing now-a-days. It also poses a huge confront to pregnant females as it is linked with unfavourable perinatal and maternal outcomes. Still, various studies revealed conflicting results between improvement in pregnancy outcome and lifestyle intervention. The objective of present review is to emphasize about complications, clinical significance and management of maternal obesity.","PeriodicalId":13288,"journal":{"name":"Indian Journal of Obstetrics and Gynecology Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82348104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：